Abstract P3-11-14: Is pathologic complete response (pCR) a valid marker of outcome even in large breast cancer? Clinical results from a neoadjuvant trial using a combination of epirubicin, docetaxel and bevacizumab (PROMIX)

Thomas Hatschek,Judith Bjöhle,Elisabet Lidbrink,Tobias Lekberg,Niklas Loman,Anna von Wachenfeldt Väppling,Martin Söderberg,Zakaria Einbeigi,Lena Carlsson,Henrik Lindman,Irma Fredriksson,Jan Frisell,Lars Löfgren,Lisa Rydén,Mats Hellström,Mårten Fernö,Jonas Bergh

Abstract P3-11-14: Is pathologic complete response (pCR) a valid marker of outcome even in large breast cancer? Clinical results from a neoadjuvant trial using a combination of epirubicin, docetaxel and bevacizumab (PROMIX)

2015

Thomas Hatschek
Judith Bjöhle
Elisabet Lidbrink
Tobias Lekberg
Niklas Loman
Anna von Wachenfeldt Väppling
Martin Söderberg
Zakaria Einbeigi
Lena Carlsson
Henrik Lindman
Irma Fredriksson
Jan Frisell
Lars Löfgren
Lisa Rydén
Mats Hellström
Mårten Fernö
Jonas Bergh

Is pathologic complete response (pCR) a valid marker of outcome even in large breast cancer? : Clinical results from a neoadjuvant trial using a combination of epirubicin, docetaxel and bevacizumab (PROMIX)

Keywords:

Cancer
Immunology
Bevacizumab
Oncology
Epirubicin
Internal medicine
Pathology
Large breast
Docetaxel
Medicine
Biopsy
Breast cancer
Gynecology
Neoadjuvant therapy
Mammography

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations